Colossal Sues Ex-Executive Over Alleged Trade Secrets

The lawsuit alleges the same knowhow underpins Colossal's de-extinction work and a rival medicine-manufacturing start-up.

Updated on Nov. 6, 2026 in Biotech

Colossal Sues Ex-Executive Over Alleged Trade Secrets

Colossal Biosciences has sued former senior executive James Kehler in US federal court in Texas, alleging he took confidential information and trade secrets before joining Neion Bio. Kehler did not immediately respond to a request for comment. The lawsuit is a legal filing; the allegations have not been tested in court.

Why it matters

The suit centers on a claim that knowhow behind Colossal's de-extinction work and Neion's medicine-manufacturing processes overlaps, which would make the dispute a test of how much specialized biotech methods can move between competing ventures. Colossal alleges Kehler took the information to advance his projects at multiple competing companies.

The lawsuit is a legal filing, so its evidence is a set of allegations rather than measured results. The source reports the $10.2bn valuation from January 2025 as context but does not give benchmark figures, and it is unresolved whether any of the alleged material was used.

The players

Colossal Biosciences

A Dallas-based de-extinction company launched in 2021 that is developing projects to bring back the dire wolf, moa and dodo.

James Kehler

A former senior Colossal executive involved in its de-extinction and allergen-free cat research who is a co-founder of Felix Pets.

Neion Bio

A start-up that manufactures medicines in chicken eggs and hired Kehler in April 2026.

Felix Pets

A company co-founded by Kehler that is attempting to develop gene-edited cats for people with allergies.

The details

The complaint alleges Kehler used his Colossal laptop to move confidential and trade-secret files to a personal cloud account and personal devices before leaving the company. Colossal says the knowhow behind its de-extinction project and Neion's manufacturing processes are the same, which is the basis for its claim that the material was carried into a competing venture. Neion Bio manufactures medicines inside chicken eggs, a method that uses living embryos as production hosts.

Timeline

  1. January 2025: Colossal valued at $10.2bn in a funding round led by TWG Global.

  2. April 2025: Colossal claimed it restored the dire wolf by editing the grey wolf genome.

  3. April 2026: Kehler joined Neion Bio.

  4. Friday: Colossal filed the lawsuit in US federal court in Texas.

  5. 2027: Felix Pets expects to have allergen-free kittens available for purchase.

The Tech Race

Colossal's dire wolf claim in April 2025 set it apart in de-extinction research, and the company was valued at $10.2bn in January 2025. The lawsuit shows that the competition for specialized biotech talent and methods is now being fought in court as well as in the lab.

The lawsuit does not change any product available to consumers today. Felix Pets expects to offer allergen-free kittens for purchase in 2027, but the source does not confirm that timeline will hold given the dispute.

The takeaway

Watch whether the Texas court sets a schedule for the trade-secret claims in the coming months. The outcome will show how courts treat knowhow claims when the same technical methods are used across different biotech applications.

Further reading

For related coverage, see the Biotech section.